

CORRECTION

Correction to: Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained

Matti Aapro¹ · Andriy Krendyukov² · Martin Schiestl³ · Pere Gascón⁴

Published online: 28 February 2018
© Springer International Publishing AG, part of Springer Nature 2018

Correction to: BioDrugs

<https://doi.org/10.1007/s40259-018-0262-9>

Figure 1, HX575 column, 5th box down, which previously read “SC HX575 vs. Eprex[®]/Erypo[®] 417 patients with CKD-related anemia” as shown here,

The original article can be found online at <https://doi.org/10.1007/s40259-018-0262-9>.


✉ Andriy Krendyukov
andriy.krendyukov@sandoz.com

¹ Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland

² Hematology/Nephrology, Sandoz Biopharmaceuticals, HEXAL AG, Industriestr. 25, 83607 Holzkirchen, Germany

³ Sandoz Biopharmaceuticals, Sandoz International GmbH, Kundl, Austria

⁴ Department of Hematology-Oncology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain



should read “SC HX575 417 patients with CKD-related anemia” as shown below.

